NMO was largely considered a subtype of multiple sclerosis (MS), until 2004 when Lennon and colleagues identified that autoantibodies directed towards aquaporin‐4 (AQP4-IgG, also called NMO-IgG) were a biomarker for NMO pathology (4). This evidence concerns the gene AQP4 and myeloid sarcoma.